Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

SynAct Pharma

17.82 SEK

-1.44 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.44 %
-25.13 %
-21.15 %
-16.14 %
-3.99 %
+12.78 %
-76.28 %
-66.79 %
+286.59 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
950.34M SEK
Turnover
2.43M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18/2
2026

Annual report '25

27/5
2026

Interim report Q1'26

11/6
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release11 hours ago

Återköp av aktier i Synact Pharma AB

SynAct Pharma
Regulatory press release11 hours ago

Repurchase of shares in Synact Pharma AB

SynAct Pharma
Press release2/9/2026, 11:00 AM

SynAct håller kapitalmarknadsdag i Stockholm den 11 mars

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/9/2026, 11:00 AM

SynAct Pharma to host Capital Markets Day in Stockholm on March 11

SynAct Pharma
Press release2/9/2026, 9:58 AM

Redeye: SynAct Pharma: Last Patient Included

SynAct Pharma
Press release2/6/2026, 4:30 PM

SynAct Pharma har framgångsrikt uppnått rekryteringsmålet i fas 2b-studien ADVANCE

SynAct Pharma
Press release2/6/2026, 4:30 PM

SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study

SynAct Pharma
Press release1/30/2026, 4:30 PM

SynAct Pharma startar fas 2-studie i patienter med respiratorisk insufficiens

SynAct Pharma
Press release1/30/2026, 4:30 PM

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma
Regulatory press release1/28/2026, 8:58 AM

Finansinspektionen: Flaggningsmeddelande i SynAct Pharma AB

SynAct Pharma
Regulatory press release1/19/2026, 7:00 AM

SynAct Pharmas utser Malin Wikstrand till tillförordnad CFO

SynAct Pharma
Regulatory press release1/19/2026, 7:00 AM

SynAct Pharma appoints Malin Wikstrand as interim CFO

SynAct Pharma
Regulatory press release1/9/2026, 6:16 PM

Styrelsen för SynAct Pharma AB (publ) har beslutat om återköp av egna aktier

SynAct Pharma
Regulatory press release1/9/2026, 6:16 PM

The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares

SynAct Pharma
Press release1/2/2026, 1:00 PM

BioStock: SynAct Pharma växlar upp inför 2026 och ADVANCE-resultaten

SynAct Pharma
Press release1/2/2026, 1:00 PM

BioStock: SynAct Pharma kicks off 2026 ahead of ADVANCE results

SynAct Pharma
Press release12/23/2025, 7:00 AM

SynAct Pharmas styrelse och ledning ingår lock-up avtal

SynAct Pharma
Press release12/23/2025, 7:00 AM

SynAct Pharma Board of Directors and Management Enter Lock-up Agreements

SynAct Pharma
Press release12/22/2025, 8:29 AM

BioStock: SynAct Pharma: ”2026 is going to be a busy year”

SynAct Pharma
Press release12/22/2025, 8:29 AM

BioStock: SynAct Pharma: ”2026 is going to be a busy year ”

SynAct Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.